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ABSTRACT: Identiﬁcation of correct protein−ligand binding poses is
important in structure-based drug design and crucial for the evaluation of
protein−ligand binding aﬃnity. Protein−ligand coordinates are commonly
obtained from crystallography experiments that provide a static model of an
ensemble of conformations. Binding pose metadynamics (BPMD) is an
enhanced sampling method that allows for an eﬃcient assessment of ligand
stability in solution. Ligand poses that are unstable under the bias of the
metadynamics simulation are expected to be infrequently occupied in the
energy landscape, thus making minimal contributions to the binding aﬃnity.
Here, the robustness of the method is studied using crystal structures with
ligands known to be incorrectly modeled, as well as 63 structurally diverse
crystal structures with ligand ﬁt to electron density from the Twilight
database. Results show that BPMD can successfully diﬀerentiate compounds
whose binding pose is not supported by the electron density from those
with well-deﬁned electron density.
■ INTRODUCTION
Crystallographic studies of ligands bound to biological
macromolecules (proteins and nucleic acids) play a key role
in structure-based drug design (SBDD). The presence of
ligands in crystal structures must be supported by convincing
experimental evidence, which is represented by the electron
density (ED). The interpretation of the observed ED in a
binding site as the ligand of interest or water or buﬀer
molecules is far from trivial; it is a subjective work that requires
good judgment and expertise, but sometimes mistakes can lead
to erroneous modeling decisions in crystal structures. The
visualization of the ligand−protein model together with the ED
maps can be a useful way for assessing ligand placement, but a
numerical measurement to quantify ligand reliability is also
required to allow a more consistent classiﬁcation. For example,
the most commonly used comparison metric is the real space
correlation coeﬃcient1,2 (RSCC). It is a local measure of how
well the calculated ED density of a ligand matches the
observed ED ranging between 1 (perfect correlation) and −1
(perfect anticorrelation) with values below 0.8, indicating a
poor ﬁt where the ligand might have been incorrectly modeled.
The “consumers” of the structural information are often not
expert crystallographers; therefore, the usage of misinterpreted
crystal structures as the starting point of computational
experiments such as ligand docking, active site identiﬁcation,
and lead optimization could lead to unreliable results from
which erroneous conclusions are consequently drawn. As
reported in several papers,3−7 there are still cases in the Protein
Data Bank (PDB, http://www.pdb.org) in which the presence
and/or location of the ligand is not fully supported by the
underlying ED. Given the fundamental importance of the
crystal structures in the progression of SBDD projects, several
tools that rank and assess their quality based on the ﬁt of the
ED have been developed.8−10 In the present paper, the
possibility to identify and separate ligands that are correctly
placed and supported by ED from those that are misplaced
and/or not supported by ED is studied with computational
methods.
If the structural ﬂexibility of a biological system needs to be
studied, molecular dynamics (MD) simulation is the technique
of choice. However, when an eﬃcient sampling of structural
dynamics is required in a limited timescale, enhanced sampling
methods such as metadynamics are often more useful.
Metadynamics11,12 enables sampling of a complex free-energy
landscape by adding a history-dependent bias into the system
as a function of a carefully chosen collective variable (CV). In
this way, the system is discouraged from revisiting previously
sampled regions and at the same time is forced to escape stable
free-energy minima, where it would normally be trapped,
facilitating the exploration of the entire free-energy landscape.
Such a methodology has been used to reconstruct the full free-
energy landscape of protein−ligand binding13−15 and predict
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the ligand binding pose. Binding pose metadynamics16
(BPMD), a variation of metadynamics, is an automated,
enhanced sampling, metadynamics-based protocol, in which
the ligand is forced to move in and around its binding pose,
whose higher mobility under the biasing potential is
considered indicative of binding mode instability. Clark et
al.,16 the developers of the tool, showed the ability of BPMD to
reliably discriminate between the correct ligand binding pose
and plausible alternatives generated with Induced Fit Docking
(IFD).
The aim of this paper is primarily to validate the BPMD tool
using reliable and questionable protein−ligand binding poses
obtained from crystal structures, identiﬁed using both RSCC
value and analysis of the ED maps. It is hypothesized that
ligands supported by underlying ED should display stability
under the BPMD bias, whereas rapid ligand ﬂuctuations,
indicating instability, are expected for ligands that are
misplaced in the ED and/or are not in a well-deﬁned energy
minimum. These studies will help to understand how the
stability of ligand binding poses could inform on crystal
structures in which the ligand has been incorrectly or
questionably modeled and potentially expand the BPMD
tool usage to assess the quality of crystal structures before
undertaking SBDD campaigns.
■ METHODS
Data Sets. The ﬁrst three test cases were identiﬁed by
searching the primary literature: epothilone17−20 bound to
tubulin alpha-1β chain protein, ampicillin21 bound to
penicillin-binding protein, and a ligand bound to IκB kinase
β.22 Extra cases were identiﬁed from the RCSB PDB in a
semiautomated fashion. The RSCC1,2 is a local measure of
how well the calculated density of a ligand matches the
observed ED and is deﬁned as
ρ ρ
ρ ρ
=
[ ]
RSCC
cov( , )
var( )var( )
obs calc
obs calc
1/2
where ρ’s are the ED values at grid points that cover the
residue in question, obs and calc refer to the experimental and
model ED, respectively, and cov and var are the sample
covariance and variance, respectively. RSCC is a statistical
measurement which is publicly available for deposited PDB
structures through the Protein Data Bank in Europe (PDBe;
http://pdbe.org/). In the worldwide Protein Data Bank
(wwPDB) X-ray validation report, it is stated that a RSCC
value above 0.95 normally indicates a good ﬁt, whereas a poor
ﬁt results in a RSCC value around or below 0.8. All the ligands
present in the PDB with RSCC annotation were taken from
the Twilight8 database and were merged with their Uniprot
(https://uniprot.org/) entry name as found in the primary
structure section of the PDB ﬁle (DBREF section). In this way,
all the proteins in which at least one structure was present with
RSCC < 0.8 (ligand not fully supported by the underlying ED)
and one with RSCC > 0.9 (ligand with good ED ﬁt) were
selected; the set of two structures with diﬀerent ligands but
same Uniprot entry will be referred to as a “pair”. Furthermore,
crystal structures with resolution worse than 2.5 Å were
discarded as well as all the proteins in which the biological
assembly was not monomeric. A total of about 11,000
structures were retrieved, and ligands that are part of the
crystallization buﬀer or solvent were removed (7538 total
structures). The number of structures was further reduced by
grouping them with their Uniprot entry name and RSCC
value. A representative member of each protein was visually
inspected; all the structures of that protein were discarded if
the protein was challenging to model; for example, it contained
unresolved portions or was diﬃcult to parameterize. This
procedure provided a set of 63 structures (61 unique ligands)
as a reference set to validate the BPMD tool. Because it was
diﬃcult to ﬁnd suﬃcient pairs for the data set, the 2.5 Å
resolution criterion was relaxed to allow ﬁve extra structures
(PDB: 2ITY, 3W16, 3QCQ, 4QE8, and 5HIB) to be selected.
The (2mFo−DFc) maps and the (mFo−DFc) maps for the
reference data set were downloaded from the PDBe database
(http://www.ebi.ac.uk/pdbe/) contoured at +1σ and ±3σ,
respectively, and visually inspected with Coot.23 Fo and Fc are
the experimentally measured and model-based amplitudes,
respectively, m is the ﬁgure of merit, and D is the σA weighting
factor.24 In general, protein−ligand models with RSCC < 0.8
have poor ligand ED ﬁt. This can range from complete absence
of ED for signiﬁcant portions of the ligand to broken ED
throughout the entirety of the ligand.6 A low RSCC score can
also be the result of a combination of good ED ﬁt for the
portions of the ligand interacting with the protein target and
the remaining portion(s) having very poor ED ﬁt because of
high ligand moiety mobility. It is clear that the interpretation of
the ﬁnal ED ﬁt is a subjective process, and there is likely to be a
wider range of individual ﬁtting interpretations when the ED is
poorly deﬁned.
In this work, we want to address the capability of BPMD to
discriminate between high- and low-probability ligand binding
modes; therefore, it is important to separate cases in which the
ED is almost absent, indicating that the ligand presence is not
supported by experimental evidence, from cases where the ED
quality does not allow a complete determination of the ligand
pose because of partial disorder, indicating that the ligand
presence is partially supported by ED. In order to better deﬁne
the data set, omit maps were calculated with σA style maximum
likelihood-weighted mFo−DFc and 2mFo−DFc map coef-
ﬁcients for all the structures by removing the ligand in question
followed by maximum likelihood reﬁnement in REFMAC.25
The omit map here refers to the fact that the ligand is omitted
from the model reﬁnement to reduce model bias in the ED
map. If the ligand molecule is present, the shape of the
resulting diﬀerence ED will provide corresponding evidence.
After the omit map was created and visually inspected with the
original coordinates overlaid, the data set was more accurately
divided in three distinct categories (Table 1): (1) green:
ligands with RSCC > 0.9 that show very good ﬁt with the ED;
(2) amber: ligands with RSCC < 0.8 that are only partially
supported by the ED, that is, the ligand presence showing
partially occupied and/or disordered portions and a fractional
positive diﬀerence density is observed in the (mFo−DFc) omit
Table 1. Overall Classiﬁcation of the Data Set Used for
Validating the BPMD Toola
category number of structures
green: ligand supported by ED 29 (30)
amber: ligand partially supported by ED 18
red: ligand with ambiguous density 16 (21)
aThe number in parenthesis represents the overall number of ligands
identiﬁed from both manual literature search and Twilight database
ﬁltering.
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maps; (3) red: ligands with RSCC < 0.8 that have no moieties
supported by the ED; that is, in the (2mFo−DFc) map, there is
no ED that could explain the ligand, no interpretable positive
diﬀerence ED in the (mFo−DFc) omit maps and/or presence
of negative diﬀerence density.
System Preparation. Complexes were downloaded from
the PDB and prepared with the Protein Preparation Wizard26
in Maestro v.2018.04. Hydrogen atoms and missing residues
were added to the initial coordinates; bond orders were
assigned to the ligand in the crystal structures. The protein
termini were capped with ACE and NMA residues. Epik was
used to ﬁnd the most likely protonation state of the ligand and
the energy penalties associated with alternate protonation
states. The protein’s hydrogen bond network was optimized
using the ProtAssign algorithm in the H-Bond Reﬁne Tab of
the Protein Preparation Wizard (Maestro v.2018.04) by
correcting both potentially transposed heavy atoms in
asparagine, glutamine, and histidine side chains and also the
protonation states of histidine residues. Finally, a restrained
minimization using the Impref module of Impact with the
OPLS3e27 force ﬁeld was used such that hydrogen atoms were
freely minimized while allowing for suﬃcient heavy atom
movement to relax strained bonds, angles, and clashes. The
Force Field Builder (FFBuilder) tool was used to automatically
generate accurate force ﬁeld torsional parameters derived from
quantum mechanics for all ligands containing substructures not
fully covered by the standard OPLS3e parameters.
Binding Pose Metadynamics. BPMD as implemented in
Maestro v.2018.4 is a variation of metadynamics simulation in
which 10 independent metadynamics simulations of 10 ns are
performed using CV as the measure of the root-mean-square
deviation (rmsd) of the ligand heavy atoms relative to their
starting position. The alignment prior to the rmsd calculation
was done by selecting protein residues within 3 Å of the ligand.
The CAs of these binding site residues were then aligned to
those of the ﬁrst frame of the metadynamics trajectory before
calculating the heavy atom rmsd to the ligand conformation in
the ﬁrst frame. The hill height and width were set to 0.05 kcal/
mol (about 1/10 of the characteristic thermal energy of the
system, kBT) and 0.02 Å, respectively. Before the actual
metadynamics run, the system was solvated in a box of SPC/E
water molecules followed by several minimization and
restrained MD steps that allow the system to slowly reach
the desired temperature of 300 K as well as releasing any bad
contacts and/or strain in the initial starting structure. The ﬁnal
snapshot of the short unbiased MD simulation of 0.5 ns is then
used as the reference for the following metadynamics
production phase.
The key concept in BPMD is that under the same biasing
force, ligands that are not stably bound to the receptor will
experience a higher ﬂuctuation in their rmsd as compared to
the stably bound ones. Three scores are provided by BPMD
that are related to the stability of the ligand during the course
of the metadynamics simulations: (1) PoseScore indicative of
the average rmsd from the starting pose. Rapid increase in the
PoseScore is indicative of ligands that are not in a well-deﬁned
energy minimum and hence might not have been accurately
modeled. (2) PersistenceScore (PersScore) is a measure of the
hydrogen bond persistence calculated as the fraction of the
frames in the last 2 ns of the simulation that have the same
hydrogen bonds as the input structure, averaged over all the 10
repeat simulations. Low PersScore is found in structures in
which their contact network is weakened by the BPMD bias. It
ranges between 0, indicating that either the ligand at the start
did not have any interaction with the protein or that the
interactions were lost in due course, and 1, indicating that the
interactions between the starting ligand binding mode and the
last 2 ns of the simulations are fully kept. (3) CompositeScore
(CompScore) is a linear combination of PoseScore and
PersScore obtained from ﬁtting the results on 42 diﬀerent
systems from the primary paper16 and is calculated as follows:
CompScore = PoseScore − 5 × PersScore.
■ RESULTS
Each complex was run using Desmond on a single node with 4
GPU cards, taking for a typical system (1 complex = 1 × 10
metadynamics run), 2−3 h. The results were assessed for pose
stability based on the PoseScore, that is, the rmsd of the ligand
with respect to the initial ligand heavy atoms coordinates. A
PoseScore ≤ 2 Å was considered stable (this value of rmsd is
often used as a threshold deﬁning success in prospective
docking simulations). In addition, the results were also
analyzed looking at the PersScore, which is an indication of
the strength of the hydrogen bonds formed between the ligand
Figure 1. Summary of EpoA results. (A) Binding site and surface of tubulin alpha-1β chain complexed with EpoA. (PDB: 4I50 blue color, upper
left corner; and PDB: 1TVK green color, lower left corner). The protein structures were aligned using the backbone; the ligand rmsd between the
two structures is 9.35 Å. Hydrogen bonds between EpoA and protein are shown with yellow dashed lines. (B) Structure of EpoA. (C) Average
rmsd of EpoA during the 10 × 10 ns metadynamics runs in PDB: 4I50 (blue line) and 1TVK (green line).
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and the protein residues. If 60% of the total hydrogen bonds
were kept during the simulations (e.g., PersScore ≥ 0.6), it was
considered as a sign of good persistence. Finally, the linear
combination of the two scores, CompScore, was also
investigated but not used as a primary metric to assess pose
stability as reported in the Results from Twilight Database
section.
Results from Initial Literature Search. The evaluation of
BPMD started from three well-characterized literature cases
which are representative of problematic situations: (1) ligand
with incorrect ligand binding mode [epothilone A (EpoA) in
tubulin alpha-1β chain]; (2) ligand placed into ED belonging
to another entity [ampicillin in penicillin-binding protein 4];
and (3) ligand modeled with incorrect geometry [inhibitor in
IκB kinase β]. Each case will be discussed in detail in the
following sections.
Tubulin Alpha-1β Chain. Epothilones are natural com-
pounds belonging to the microtubule stabilizing antimycotic
agent class that bind to the common binding site in β-tubulin.
The ﬁrst atomic model of EpoA (Figure 1B) bound to α,β-
tubulin was solved by Nettles et al.19 with a combined
approach of electron crystallography, NMR, and molecular
modeling in 2004 (PDB: 1TVK). Serious doubts have been
raised for the proposed bound conformation of EpoA in this
model because of the inconsistencies with NMR information.
In fact, in 2013, Prota et al.20 deposited a 2.3 Å X-ray crystal
structure of EpoA in complex with α,β-tubulin, the stathmin-
like protein RB3, and tubulin tyrosine ligase (PDB: 4I50),
which showed a diﬀerent binding mode for the ligand as
compared to the 1TVK model (Figure 1A). For these reasons,
the structure of tubulin alpha-1β chain in complex with EpoA
was employed to examine the ability of BPMD to diﬀerentiate
between the correct and incorrect ligand binding mode.
During the metadynamics calculation on the initial structure
(1TVK), EpoA shows an average rmsd over the 10 runs that
increased from the beginning to the end of the simulation time,
and the hydrogen bonds were present for a limited time of the
simulation run (Figure 1C). The overall PoseScore and
PersScore are 4.0 and 0.1, respectively. Both these observations
are indicative of the instability of the binding mode and are
consistent with reports questioning the original structure. On
the other hand, EpoA in 4I50 shows a diﬀerent behavior,
where the averaged rmsd reaches a steady PoseScore of 0.9
that is kept constant until the end of the simulations (Figure
1C). At the same time, the PersScore indicates that the
hydrogen bonds identiﬁed at the start of the metadynamics run
are kept for 70% of the averaged time. In this case, the results
suggest a stable binding mode. There is a clear diﬀerence
between the original structure (1TVK) and the more recent
one (4I50) both in the PoseScore and the overall rmsd proﬁle
during the metadynamics run, showing, in this case, that
BPMD can diﬀerentiate between a stable and unstable binding
geometry. Another potential sign of instability for the ligand in
1TVK could also be seen in the high rmsd of up to 3.6 Å
between the 10 structures used as reference for the
metadynamics run; in 4I50, the ligand RMS deviation reaches
0.75 Å at maximum. Finally, in the case of 4I50, EpoA under
the BPMD bias experiences no drastic rearrangement as
compared to the initial pose; hence, the ligand conformation in
4I50 is in a stable conformation as opposed to the ligand
modeled in 1TVK.
Penicillin-Binding Protein 4. Penicillin-binding proteins are
membrane-associated proteins that catalyze the ﬁnal step of
murein biosynthesis in bacteria. Penicillins bind irreversibly to
the active site of those enzymes disrupting the cell wall
synthesis. The crystal structure of the penicillin binding protein
4 from staphylococcus aureus in complex with ampicillin
(PDB: 3HUN,21 resolution 2 Å) was deposited in 2010,
showing two separate chains in the asymmetric unit, although
the preferred biological assembly of the complex is monomeric.
In each of the deposited chains, A and B, ampicillin is modeled
with a diﬀerent binding mode and the RSCC is low, suggesting
that there is poor ﬁt between observed and modeled ED:
RSCCchain A = 0.52 and RSCCchain B = 0.73 (Supporting
Information). Moreover, as stated by Weichenberger et al.,28
the phenyl moiety of ampicillin (ZZ7-501, chain B) is placed in
a density that could better ﬁt a sulfate ion. Therefore, each
chain containing the ligand ampicillin was submitted to the
BPMD protocol. The PoseScore of ampicillin in chains A and
B are 4.6 and 5.1, respectively (Figure 2). The high rmsd from
the reference conformation of the ligand and the weakened
hydrogen bond network during the simulations are consistent
with the fact that the ED does not support the ligand presence
in either of the chains.
IκB Kinase β. The structure of IκB kinase β bound to the
ligand, as depicted in Figure 3B, was solved at a resolution of
3.6 Å and deposited as PDB code 3QAD.22 This has been the
focus of several papers concerning protein−ligand crystal
structures with poorly reﬁned ligand geometries.5,6 In this
crystal structure, the aminopyrimidine ring of the bound
inhibitor had a pyramidal carbon in the pyrimidine ring instead
of the expected planar one, and the piperazine moiety is in an
unfavorable boat conformation (Figure 3A). The authors
released a second structure (PDB: 3RZF) after re-reﬁnement
of the erroneous one. However, even in the newly released
structure, the ligand is highly strained.29 Moreover, by
analyzing the deposited ED, as explained in the Methods
section, the (2mFo−DFc) map does not support the presence
of the ligand. The BPMD protocol was applied to the ligand as
modeled in both crystal structures. The averaged PoseScore
and PersScore are 6.7 and 0 for the ligand in the obsolete
structure (PDB: 3QAD) and 4.9 and 0.009 for the ligand in
the reﬁned structure (PDB: 3RZF), respectively. In both cases,
the ligand rmsd increases signiﬁcantly from the starting
conformation, suggesting that the ligand binding pose is highly
Figure 2. Plot of rmsd estimate averaged over all 10 trials vs
simulation time for ampicillin from PDB: 3HUN chain A in green and
chain B in blue.
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b00843
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
D
unstable under the BPMD bias supporting the hypothesis that
the ligand is not correctly modeled in the binding site in either
crystal structure (Figure 3C).
Basic Features of Ligand Data Set and Their Protein
Target. To further validate the methodology, we identiﬁed
and analyzed a data set of 64 unique ligands bound to 32
diﬀerent proteins, resulting in a total of 69 complexes,
including the structures from manual literature search. As
reported in Figure 4, the majority of the structures have a
crystallographic resolution below 2.5 Å, except for the cases
identiﬁed from the manual literature search (PDB: 1TVK,
3QAD, 3RZF) and the ﬁve extra cases (see Methods section).
Transferases are the most well-represented structures (about
30% of the whole data set); the rest of the data set is
distributed across 11 protein families including hydrolase,
isomerase, DNA-binding protein, signaling protein, and ligase.
The ligands appear to be widely distributed in drug-like
physicochemical space, implying the generality of the data set
used (Figure 5).
Results from Twilight Database. The results of the
complexes from categories green (ligand supported by ED)
and red (ligand not supported by ED) are ﬁrst discussed. A
total of 51 crystal structures, 30 with RSCC > 0.9 and 21 with
RSCC < 0.8 that have been conﬁrmed by inspection of the ED
maps, were subjected to the BPMD protocol to assess ligand
stability. Initially, the Twilight database was searched for pairs
of compounds crystallized in the same protein, in which one
was well supported by the ED and the other was not. By
analyzing the results for pairs of structures only, where each
pair contains one structure with RSCC > 0.9 and one with
RSCC < 0.8 as deﬁned in the Methods section, it is observed
that in 7/11 pairs, a cutoﬀ of PoseScore = 2 clearly
distinguishes between structures supported by ED and those
that are not (Figure 6). In 2/11 pairs (EPHA3 and PPARG),
the structures cannot be distinguished by PoseScore, while in
2/11 pairs, the structures can be distinguished by the
PoseScore, but both fall below (BACE1) or above (ANDR)
the threshold of 2. All the test cases with RSCC > 0.9 have
PoseScore < 2, except for the androgen receptor (Figure 6).
To get a more meaningful picture of the performance of the
method, a larger data set was needed. Because it proved
diﬃcult to ﬁnd pairs of compounds from the same protein
where one of the ligands was clearly not supported by the
density, this requirement was removed, and the protocol was
tested on an expanded set as shown in Figure 7. Overall, if the
results of category green and red are analyzed ignoring the pair
deﬁnition, 28/30 crystal structures supported by the ED have a
PoseScore below the cutoﬀ threshold of 2. The only two
outliers are the surface-exposed ligand of the androgen
receptor, PDB: 2PIT, and the fragment bound to the PHIP
Figure 3. (A) Binding site of IκB kinase β in complex with inhibitor. On the left: upper corner, originally deposited crystal structure (PDB: 3QAD)
in which the ligand geometry is highly strained with a pyramidal aromatic carbon in the amino-pyrimidine moiety and the piperazine ring in a boat
conformation; lower corner, the redeposited but still highly strained structure is shown (PDB: 3RZF). (B) Structure of ligand. (C) Average rmsd of
ligand during the 10 × 10 ns metadynamics runs in PDB: 3QAD (green line) and 3RZF (blue line).
Figure 4. Characteristics of the protein, structures, and binding
pockets. (1) Distribution of proteins, as displayed in the PDB and
according to the Uniprot access code. (2) Distribution of crystallo-
graphic resolution values. (3) Distribution of ligand-binding pocket
volumes using SiteMap. In (2,3), the distributions are color-coded
according to the category deﬁnition: ligand supported by ED (green),
partially supported by ED (amber with tick diagonal stripes), and not
supported by ED (red with diamond grid).
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protein with six heavy atoms, PDB: 3MB3 (see Discussion
section). Conversely, 17/21 crystal structures where the ligand
is not supported by the ED have a PoseScore > 2. In general, a
PoseScore of 2 (which is indicative of the average rmsd
deviation from the starting pose) has been identiﬁed as a
practical threshold for distinguishing between stable and
unstable ligands as proposed previously by Clark and co-
workers.16 From these results, by using the number of
structures with RSCC > 0.9 and PoseScore < 2 as true
positives (TP = 28) or PoseScore > 2 as false negative (FN =
2) and with RSCC < 0.8 and PoseScore > 2 as true negatives
(TN = 17) or PoseScore < 2 as false positive (FP = 4),
combining structures found both in the literature with manual
search and in the Twilight database (Table 2), the confusion
matrix of the PoseScore (Table 3) gave a sensitivity of 0.94, a
speciﬁcity of 0.84, and a κ value of 0.78, which conﬁrmed the
ability of BPMD to correctly separate the crystal structures
Figure 5. Selected physicochemical properties of the data set. From the upper left: number of sp3 carbons, heavy atoms, and aromatic rings, log D
at pH = 7.4, number of rotatable bonds, and hydrogen bond donor and acceptor. The histograms are color-coded by the ligand category deﬁnition:
green, ligand supported by ED, red with diamond grid, ligand not supported by ED, and amber with tick diagonal stripes, ligand with ambiguous
density.
Figure 6. PoseScore overview of complexes shown by protein in pairs.
Test cases are color-coded by ED (red and cross shape = the
underlying density is too poor to model the ligand, green and circle
shape = density is present). On the y-axis, a cutoﬀ at a PoseScore
equal to 2 is reported to identify ligands that are stable during the
course of the BPMD runs.
Figure 7. PoseScore of all the test cases supported by ED, in green
and circle, and not supported by ED in red and cross.
Table 2. Confusion Matrix of the Structures from the Green
and Red Category Which Are Supported and Not by ED
Using PoseScore as a Metric
PoseScore < 2 PoseScore > 2 total
green: RSCC > 0.9 28 2 30
red: RSCC < 0.80 4 17 21
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.9b00843
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
F
where the ligand has a satisfactory ED from crystal structures
where the ED does not explain the ligand placement. The
general trend previously observed for the initial test cases
identiﬁed by manual search of the literature has proven to be
generalizable. This separation of the two classes of ligands also
gives conﬁdence that the force ﬁeld is performing well. The
stability of the green ligands under BPMD bias suggests that
the instability of the red ligands is not a consequence of issues
with the force ﬁeld. Indeed, the OPLS3e27 force ﬁeld is well
validated for drug-like ligands and has been show to perform
well in comparison to other ligand force ﬁelds such as those in
CHARMM,30 AMBER,31 and older versions of OPLS.27
The overall results were also analyzed by PersScore (Figure
8). The correct threshold to separate green and red categories
is more diﬃcult to identify unambiguously for PersScore as
compared to PoseScore. However, if a threshold of 0.6 is
adopted, which corresponds to 60% of the interactions being
maintained on average across all 10 simulations, 23 out of 30
of the ligands supported by ED are correctly identiﬁed, while
in the remaining 7 cases, the interaction networks were kept
between 40 and 57% of the total averaged simulation time. The
fragment in PDB: 3MB3, scored as unstable by the PoseScore
metric, is the only example with RSCC > 0.9 that had no
hydrogen bonds at the start of the simulation. The absolute
numbers of ligands in the red category that fell below and
above the threshold of 0.6 were equal to the number of
complexes identiﬁed by the PoseScore threshold: 17 red
protein−ligand complexes have an interaction network that is
signiﬁcantly altered by the BPMD bias and in 4 red cases the
network is preserved. The sensitivity, speciﬁcity, and κ value if
the PersScore is used to evaluate ligand stability are 0.81, 0.84,
and 0.58, respectively. The PoseScore appears to be a better
metric to separate cases where the ligand is correctly modeled
in the ED from those which are not. Finally, the CompScore,
which is a combination of the PersScore and PoseScore, gives
results that are comparable to PoseScore. As a further
comparison of the scores, a bootstrapping study was carried
out to estimate the standard errors associated with each metric,
using three crystal structures selected from the red and green
categories (Supporting Information). The results of this study
combined with the analysis above showed that PoseScore is the
preferred metric because it can be estimated with greater
precision than CompScore and is easier to interpret than the
PersScore. We note in passing that CompScore is normally
preferred when BPMD is used to rank docking poses.32
Analysis of Structures in the “Twilight” Data Set.
Inspection of the ED maps of the ligands belonging to the
amber category revealed that the regions of the ligand that
were not supported by ED were often outside the binding site
and solvent-exposed while the regions inside the protein
binding site were mainly supported by the ED (Figure 9). For
some of these cases, the ligands may be stable even though
they have a low RSCC. Hence, a BPMD PoseScore below the
threshold of 2 might be expected.
The percentage of ligand atoms that are uncovered by the
ED in the amber category varies from about 6−38%, signifying
that most of the ligand is supported by the density with some
portion that is not supported by experimental evidence. It is
observed that the ligand PoseScore increases with increasing
disorder in the ligand structure with a r2 of 0.54 (Figure 10).
The ligand BJI in PDB: 2JKO is about 26% uncovered by the
ED, and given the trend of the other structures in the amber
category, it could be thought to be unstable. Its predicted
BPMD PoseScore is 1.1, suggesting high ligand stability. After
inspecting the original publication,36 this is not surprising
because the reasoning behind its design was not to add new
protein ligand interactions but to improve the ligand solubility
without aﬀecting potency by including a piperazine ring36 that
is solvent-exposed (Figure 9, panel 4). Therefore, the high
ligand stability obtained from BPMD conﬁrms the hypothesis
that the piperazine ring would not be detrimental to the
Table 3. Summary Statistics for the Green and Red
Category Which Are Supported or Not by ED Using
PoseScore as a Metrica
sensitivity 0.94
speciﬁcity 0.84
precision 0.88
accuracy 0.88
negative predictive value 0.81
κ 0.78
aStatistics were generated by using the green scored with PoseScore <
2 as true positive (28) or PoseScore > 2 as false negative (2), the red
scored with PoseScore < 2 as false positive (4), or PoseScore > 2 as
true negative (17).
Figure 8. PersScore of all the test cases supported by ED, in green
and circle, and not supported by ED in red and cross.
Figure 9. Examples of ligands belonging to amber category in which
the portion not described by the ED is solvent-exposed and not
interacting with the protein. The (2mFo−DFc) map contoured at 1σ
is shown as a wireframe and the protein is in cartoon representation.
(1) PDB: 4D2R,33 ligand DYK, RSCC = 0.68; (2) PDB: 5P9H,34
ligand 7G7, RSCC = 0.76; (3) PDB: 2ITY,35 ligand IRE, RSCC =
0.76; and (4) PDB: 2JKO,36 ligand BJI with RSCC = 0.84.
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stability of the ligand’s binding mode, and the structural result
can be trusted regardless of the missing ED.
■ DISCUSSION
Overall, BPMD showed good ability to identify ligands whose
modeled pose is not supported by their ED (Figures 6 and 7),
even for the cases in which the ligand is only partially
supported by the ED (Figure 10). Investigating the results in
more detail reveals some insights into situations that can be
challenging for the method and caveats users should be aware
of, which are worthy of further discussion. Before being
submitted to the ﬁnal metadynamics simulation, every complex
underwent an equilibration procedure as explained in the
Methods section. The last step of the last short unbiased MD
simulation (0.5 ns) is used as the reference structure for the
PoseScore calculation. Consequently, the reference structure
for BPMD is not the input structure but the equilibrated one
which can, in some cases, diﬀer signiﬁcantly. Given this
observation, the PoseScore was compared to the rmsd between
the initial crystal structure and the reference equilibrated
structure, which is here called MD-rmsd, to understand if
unstable poses could be ﬂagged in advance from the MD
equilibration procedure. The PoseScore correlates with the
MD-rmsd, that is, the average displacement among the
reference structures with a r2 of 0.75 (Figure 11): the higher
the MD-rmsd from the originally deposited structure, the more
likely the ligand will be unstable.
It should be noted that the rmsd between the 10 reference
structures can be quite signiﬁcant, especially in the cases of the
red category (Figure 11) and in the region of MD-rmsd > 3 Å.
Here, the conformation of the ligand reference structures is not
a very good representation of the initial crystal structures. The
high correlation between PoseScore and MD-rmsd (Figure 11)
suggests that MD-rmsd could be used as a preliminary
indication that the initial structure is not correctly modeled.
When a shorter equilibration step of 10 ps instead of 500 ps is
used for all the cases in which at least one reference structure
shows a rmsd ≥ 3 Å, a systematic decrease of MD-rmsd is
observed, while the PoseScore does not change signiﬁcantly,
conﬁrming that the ligand in those structures are highly
unstable (Figure 12).
In the region of MD-rmsd up to 2 Å (Figure 13), the average
reference structure can be considered close enough to the
initial starting structure as opposed to the ones in the region
with MD-rmsd > 2.5 Å. The ligands in the green category have
lower structural variability (low MD-rmsd), in agreement with
the PoseScore below the threshold of 2. The presence of
outliers in the region of MD-rmsd between 1.3 and 2 Å (Figure
13) shows the advantage of using the metadynamics
production phase. In the case of 5XHK, 5MYM, and 4WZ1,
the beneﬁt of BPMD is clear; in fact, despite the MD-rmsd
being below 1.5 Å, which could be indicative of ligand stability,
the BPMD bias was needed to correctly classify them as
unstable (PoseScore > 2) in agreement with the missing ED
from the experiment. A diﬀerent situation is observed for
2HWQ and 5Q17 in which PoseScore is found below the
threshold of 2 and also that the MD-rmsd is lower than 2 Å.
The results obtained for this data set suggest that BPMD can
successfully discriminate between crystal structures that are
correctly modeled and those that are not, but also that the
MD-rmsd obtained from the short equilibration step might be
informative of dubious structures. A thorough investigation of
MD as compared to BPMD in identifying questionable crystal
structures is required to identify the optimum protocol to
balance accuracy against computational eﬃciency.
Several of the structures that were considered to be
misclassiﬁed by BPMD, that is, there was disagreement
between the ED classiﬁcation and the PoseScore, deserve
further discussion. The ligand 4HY found in PDB: 2PIT37
binds to the surfaced-exposed allosteric pocket called Binding
Function 3 of the androgen receptor. It has a RSCC = 0.93 but
resulted in a high PoseScore of 4.1. In the original paper,37 it is
claimed that it binds weakly (IC50 ≈ 50 μM) to the surface
weakening the contacts between the androgen receptor and
coactivator proteins. In this case of low binding aﬃnity in an
open solvent-exposed site, the ligand can be readily displaced
Figure 10. PoseScore of the structures belonging to Amber category
(ligand partially supported by ED) with respect to the percentage of
atoms that are uncovered by ED and color-coded by RSCC from low
(light-yellow) to up to 0.8 (dark-yellow).
Figure 11. PoseScore correlation with the ligand rmsd of the
reference structures obtained after the equilibration procedure, MD-
rmsd. The structures are color-coded by category: green (ligand
supported by ED, circle shape), amber (ligand partially supported by
ED, diamond shape), and red (ligand not supported by ED, cross
shape). The error bar calculated as the standard deviation of the rmsd
from each of the 10 metadynamics run is reported on top of each
point. The black line is the best ﬁt line between PoseScore and MD-
rmsd, whereas the dashed black line indicates the line y = x.
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under the BPMD bias, despite being supported by the ED. A
similar exposed pocket was observed in the case of three
ligands PDB: 5MRD, 2XPA, and 2XP6, where there is
agreement between ED and PoseScore, so this is not a
consistently observed problem.
Another interesting case is that of the MB3 ligand
crystallized in the second bromodomain of PHIP (PDB:
3MB338), which has a high RSCC value of 0.93 but showed a
PoseScore higher than 2. Interestingly, the ligand is a very
small fragment possessing only seven heavy atoms, therefore,
very diﬀerent from others investigated here and in previous
BPMD studies. It is possible that the metadynamics parameters
may not be well optimized for such a small fragment.
Among the incorrectly predicted crystal structures in the red
category, it is worth mentioning PDB: 2HWQ.39 Despite a
poor ligand RSCC score of 0.23 and ambiguous fragmented
density in the omit maps, it has a PoseScore of 1.21. The
binding pocket is narrow, and the ligand binds deep into it.
The same authors have solved structures of related ligands
bound to the same protein (PPARG) such as PDB: 2F4B40
(RSCC = 0.73) and 2HWR39 (RSCC = 0.71). Therefore, the
ligand may have been modeled by using prior knowledge from
these studies in addition to the ED. A crystal structure with
comparable ligand binding mode and good RSCC value (PDB:
5GTN41) was also solved a few years later, corroborating the
deposited ligand binding mode. Therefore, in this instance,
although the ED does not support the binding mode, the
ligand may have been correctly modeled using other
information, explaining why it is miscategorized in this work.
The cases discussed above suggest that particularly small
ligands or open binding sites may be challenging for BPMD.
To investigate whether these factors are a key inﬂuence on the
BPMD score, heavy atom count, protein−ligand H-bond
count, and binding pocket volume have been plotted against
PoseScore (Figure 14). No correlations were seen, suggesting
that these factors are not driving the prediction from
PoseScore.
Out of the 69 total structures, 34 had binding aﬃnity data as
retrieved from the primary literature citation where they were
ﬁrst discussed in the form of IC50. The binding data were
converted into pIC50, and a poor correlation was observed with
PoseScore (r2 = 0.33, see Figure 15) as opposed to what was
found by Clark et al.16 in which they use BPMD as a tool to
prioritize IFD ideas. In this work, despite the binding aﬃnity of
the ligand under investigation, if the starting position is
correctly modeled, it will result in a PoseScore below 2;
therefore, BPMD should not be regarded in this way as a tool
to prioritize ideas based on the PoseScore.
■ CONCLUSIONS
We have investigated the capabilities of the BPMD tool to
correctly identify stable ligands using a diverse data set of
crystal structures from published literature and collected from
the Twilight database. Primarily, this study has been used as a
validation that BPMD is a useful predictor of binding mode
Figure 12. Left panel: (A) PoseScore of the structures in which at least one of the reference structures has MD-rmsd > 3 Å. (B) PoseScore of the
same structures, run after a shorter unbiased MD simulation of 10 ps instead of 500 ps (called NEW_PoseScore). The MD-rmsd is below 2.5 Å for
all cases. (C) PoseScore obtained with shorter equilibration procedure (NEW_PoseScore) and with default protocol. The best ﬁt line is displayed
as a black line and y = x as a black dotted line. In general, the overall results did not change. Each structure is colored identically in A, B, and C.
Figure 13. PoseScore in the range of MD-rmsd up to 2 Å where the
reference structures can be considered similar to starting structure.
The structures identiﬁed with their PDB name represent the
advantages (5XHK, 5MYM, and 4ZW1) and potential limitation
(5Q17 and 2HWQ) of using the BPMD protocol. All the structures in
the green category show low MD-rmsd.
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stability, in agreement with previous studies looking at docking
and scoring. From the conducted validation on 69 complexes
with diﬀerent physical chemical properties, BPMD has shown
good performance categorizing ligand binding modes
supported by ED from those not supported. In particular, it
was identiﬁed that ligands supported by ED show a PoseScore
below 2 as opposed to the unsupported ones, which have a
PoseScore above 2. BPMD scores do not seem to correlate
with binding aﬃnity, suggesting that the method is useful for
assessing the stability of individual poses or the relative
stability of diﬀerent poses of the same ligand, but not for
scoring diﬀerent ligands.
From the more challenging cases in which the ligand is
partially supported by the underlying ED, it was observed that
if the disorder comes from parts of the ligand that do not
participate in any protein interaction, then the overall stability
of the ligand, given that the rest of it is correctly modeled, will
not be aﬀected. Thus, information from BPMD simulations
could help medicinal and computational chemists in designing
more potent compounds maximizing the ligand−protein
interactions where the most stable portion of the ligand lies
and incorporating ﬂexibility and solubilizing groups in the
noninteracting portion without compromising the overall
binding stability.
Aside from the validation of the methodology, the data
presented here suggest that BPMD may be a useful tool for the
crystallographer. Solving crystal structures is an expert job
incorporating information beyond that contained in the ED,
but this makes it open to a degree of subjectivity. These results
suggest that BPMD could be useful in assessing preliminary
poses generated by crystallography and highlighting those that
would need further investigation or conﬁrmation before
undertaking more time-consuming and expensive strategies.
Speciﬁc cases have been identiﬁed, which can be challenging
for BPMD, including very small fragments, surface-exposed
binding pockets, and interactions with no hydrogen bonds.
There are a number of parameters within BPMD that could be
investigated to see whether they give an improvement in these
cases, such as Gaussian width and height, choice of CV, and
run time. However, they are not investigated further here
because, overall, the default parameters oﬀer good discrim-
ination.
Finally, the average rmsd of the equilibrated structures prior
to the metadynamics simulations has appeared to be
informative of inherently unstable ligands. Interestingly, it is
observed that the reference structure used in the BPMD
protocol might have substantially changed from the input
structure especially for the cases in which the ligand is not
supported by ED. A brief investigation of using a shorter
equilibration procedure on the cases with MD-rmsd > 3 Å
showed overall unchanged results with a PoseScore that does
not change signiﬁcantly from the one obtained with the default
protocol. It would be interesting to know in a more systematic
way which protocol of unbiased MD is needed to obtain
comparable BPMD results, and this will be the subject of
further studies.
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Figure 14. Relationship between PoseScore and number of heavy atoms (A), volume of binding site (B), and hydrogen bonds (C) of the ligands in
the data set. Structures belonging to category green, ligand supported by ED are colored in green with circle shape; from category amber, ligand
partially supported by ED are in yellow with diamond shape; and from category red, ligand not supported by underlying ED are in red and with
cross shape.
Figure 15. PoseScore of all the crystal structures with pIC50 data
color-coded by category (green and circle, complexes supported by
ED; amber and diamond, complexes partially supported by ED; and
red and cross, complexes not supported by ED).
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